| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1023463208 |
| P356 | DOI | 10.1038/LEU.2016.57 |
| P932 | PMC publication ID | 4935597 |
| P698 | PubMed publication ID | 27055866 |
| P50 | author | Gheath Alatrash | Q41791172 |
| P2093 | author name string | D Li | |
| H He | |||
| Q Ma | |||
| R Hong | |||
| M J You | |||
| L St John | |||
| M Gagea | |||
| A Sergeeva | |||
| J J Molldrem | |||
| K Clise-Dwyer | |||
| K Ruisaard | |||
| P Sukhumalchandra | |||
| R Patenia | |||
| P2860 | cites work | TCR mimic monoclonal antibodies induce apoptosis of tumor cells via immune effector-independent mechanisms. | Q39599888 |
| Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. | Q39952676 | ||
| A robust xenotransplantation model for acute myeloid leukemia | Q40886338 | ||
| Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells | Q41164481 | ||
| Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model | Q41791126 | ||
| Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. | Q42635839 | ||
| Ligand recognition by alpha beta T cell receptors | Q46222293 | ||
| Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation. | Q53302219 | ||
| Macrophage and lymphocyte antibody-dependent cellular cytotoxicity in spontaneous leukemogenesis of AKR/J mice | Q69399723 | ||
| Macrophage colony-stimulating factor enhances monocyte and macrophage antibody-dependent cell-mediated cytotoxicity | Q69487079 | ||
| Natural history of central nervous system acute leukemia in adults | Q71470093 | ||
| Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units | Q73774727 | ||
| Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia | Q74268543 | ||
| Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model | Q79367320 | ||
| Rituximab: mechanism of action | Q24607358 | ||
| Conformational changes within the HLA-A1:MAGE-A1 complex induced by binding of a recombinant antibody fragment with TCR-like specificity | Q27653583 | ||
| A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo | Q27668018 | ||
| Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell | Q27861001 | ||
| A cell initiating human acute myeloid leukaemia after transplantation into SCID mice | Q28131777 | ||
| Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice | Q28242854 | ||
| Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells | Q28250509 | ||
| Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts | Q33357299 | ||
| A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias | Q33714727 | ||
| Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy | Q33769702 | ||
| Loss of mismatched HLA in leukemia after stem-cell transplantation. | Q34018719 | ||
| Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity. | Q34035564 | ||
| An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells | Q34923734 | ||
| Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice | Q35182714 | ||
| How T cells 'see' antigen | Q36045188 | ||
| Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. | Q36139709 | ||
| Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity | Q36142259 | ||
| Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex | Q36368410 | ||
| Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy. | Q36417330 | ||
| Immunotherapeutic peptide vaccination with leukemia-associated antigens | Q36548009 | ||
| Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence | Q36570359 | ||
| Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes | Q36727464 | ||
| Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia | Q37104236 | ||
| Approaching untargetable tumor-associated antigens with antibodies | Q37194869 | ||
| CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. | Q37305045 | ||
| Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. | Q37659113 | ||
| Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells | Q37809460 | ||
| TCR-like biomolecules target peptide/MHC Class I complexes on the surface of infected and cancerous cells | Q37952806 | ||
| P433 | issue | 7 | |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 1475-1484 | |
| P577 | publication date | 2016-03-08 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo | |
| P478 | volume | 30 |
| Q61813273 | A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2 |
| Q38766349 | A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells |
| Q92271274 | A novel specific cleavage of IκBα protein in acute myeloid leukemia cells involves protease PR3 |
| Q64070843 | Antigen Targets for the Development of Immunotherapies in Leukemia |
| Q37561181 | Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. |
| Q90734654 | Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer |
| Q38705015 | Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells |
| Q39631989 | PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia. |
| Q52716245 | RosettaAntibodyDesign (RAbD): A general framework for computational antibody design. |
| Q55008935 | Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. |
| Q49444213 | Targeting PR1 in myeloid leukemia |
| Q47590707 | The progress and current status of immunotherapy in acute myeloid leukemia |
| Q55354182 | Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions. |
Search more.